Professor Douglas Joshua

• Publications

Publications

2010

Nath, C, Shaw, P, Trotman, J, Zeng, L, Duffull, S, Hegarty, G, McLachlan, A, Gurney, H, Kerridge, I, Kwan, Y, Presgrave, P, Tiley, C, Joshua, D, Earl, J. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British journal of clinical pharmacology. 2010; 69:484-97

Li, J, Sze, D, Brown, R, Cowley, M, Kaplan, W, Mo, S, Yang, S, Aklilu, E, Kabani, K, Loh, Y, Yamagishi, T, Chen, Y, Ho, P, Joshua, D. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom's Macroglobulinaemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 2010; :

Reid, S, Yang, S, Brown, R, Kabani, K, Aklilu, E, Ho, P, Woodland, N, Joshua, D. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. International journal of laboratory hematology. 2010; :

2009

Burgess, P, Robin, H, Langshaw, M, Kershaw, G, Pathiraja, R, Yuen, S, Coad, C, Xiros, N, Mansy, G, Coleman, R, Brown, R, Gibson, J, Holman, R, Hubbard, J, Wick, V, Lammers, M, Johnson, R, Huffman, K, Bell, J, Ibrahim, A, Estepa, F, Lovegrove, J, Joshua, D. Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert Module. International journal of laboratory hematology. 2009; 31:603-14

Brown, R, Spencer, A, Ho, P, Kennedy, N, Kabani, K, Yang, S, Sze, D, Aklilu, E, Gibson, J, Joshua, D. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma. 2009; 50:1860-1864

Palumbo, A, Sezer, O, Kyle, R, Miguel, J, Orlowski, R, Moreau, P, Niesvizky, R, Morgan, G, Comenzo, R, Sonneveld, P, Kumar, S, Hajek, R, Giralt, S, Bringhen, S, Anderson, K, Richardson, P, Cavo, M, Davies, F, Bladé, J, Einsele, H, Dimopoulos, M, Spencer, A, Dispenzieri, A, Reiman, T, Shimizu, K, Lee, J, Attal, M, Boccadoro, M, Mateos, M, Chen, W, Ludwig, H, Joshua, D, Chim, J, Hungria, V, Turesson, I, Durie, B, Lonial, S, , I. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009; 23:1716-30

Giralt, S, Stadtmauer, E, Harousseau, J, Palumbo, A, Bensinger, W, Comenzo, R, Kumar, S, Munshi, N, Dispenzieri, A, Kyle, R, Merlini, G, San Miguel, J, Ludwig, H, Hajek, R, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M, Einsele, H, Barlogie, B, Anderson, K, Gertz, M, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Sezer, O, Mateos, M, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Richardson, P, Niesvizky, R, Rajkumar, S, Durie, B, , I. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009; 23:1904-1912

Dickinson, M, Prince, H, Kirsa, S, Zannettino, A, Gibbs, S, Mileshkin, L, O'Grady, J, Seymour, J, Szer, J, Horvath, N, Joshua, D. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal medicine journal. 2009; 39:304-316

Dispenzieri, A, Kyle, R, Merlini, G, Miguel, J, Ludwig, H, Hajek, R, Palumbo, A, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M, Comenzo, R, Einsele, H, Barlogie, B, Anderson, K, Gertz, M, Harousseau, J, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Richardson, P, Sezer, O, Mateos, M, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Rajkumar, S, Durie, B, , I. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23:215-224

2008

Joshua, D, Brown, R, Ho, P, Gibson, J. Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma. 2008; 8:283-286

Loh, Y, Mo, S, Brown, R, Yamagishi, T, Yang, S, Joshua, D, Roufogalis, B, Sze, D. Presence of Hoechst low side populations in multiple myeloma. Leukemia & Lymphoma. 2008. p. 1813-1816.

2007

Cooper, C, Joshua, D, Lee, C, Eyers, A, Cooper, W. Extranodal plasmablastic lymphoma arising in mantle cell lymphoma. Histopathology. 2007; 51:856-9

Sanders, J, Crawford, B, Gibson, J, Joy Ho, P, Iland, H, Joshua, D. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International journal of laboratory hematology. 2007. p. 395-397.

Osborne, R, De Abreu Lourenço, R, Dalton, A, Houltram, J, Dowton, D, Joshua, D, Lindeman, R, Ho, P. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2007; 10:451-456

2006

Sze, D, Brown, R, Yang, S, Ho, P, Gibson, J, Joshua, D. The use of thalidomide in myeloma therapy as an effective anticancer drug. Current cancer drug targets. 2006; 6:325-31

Ling, S, Joshua, D, Gibson, J, Young, G, Iland, H, Watson, G, Ho, P. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. American journal of hematology. 2006; 81:110-4

2005

Chan, K, Yuen, S, Joshua, D. A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia. Clinical and laboratory haematology. 2005; 27:399-401

Joshua, D. Multiple myeloma: the present and the future. Major advances continue apace in therapy and in understanding its molecular pathogenesis. The Medical journal of Australia. 2005; 183:344

Bradstock, K, Matthews, J, Lowenthal, R, Baxter, H, Catalano, J, Brighton, T, Gill, D, Eliadis, P, Joshua, D, Cannell, P, Schwarer, A, Durrant, S, Gillett, A, Koutts, J, Taylor, K, Bashford, J, Arthur, C, Enno, A, Dunlop, L, Szer, J, Leahy, M, Juneja, S, Young, G. A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood. 2005; 105:481-488

Joshua, D, Brown, R, Ho, J. Multiple myeloma: challenges and opportunities. Methods in Molecular Medicine. 2005; 113:1-4

Ling, S, Campbell, L, Ho, J, Gibson, J, Joshua, D. Multiple myeloma: molecular biology, pathology and cytogenetics. In: Clinical Malignant Haematology. New York: McGraw-Hill 2005. p. ?.

2004

Gibson, J, Ho, P, Joshua, D. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic. Transplantation proceedings. 2004; 36:2501-3

Gibson, J, Ho, P, Joshua, D. Low-grade lymphoma: the optimal timing. Transplantation proceedings. 2004; 36:1995-8

Brown, R, Murray, A, Pope, B, Sze, D, Gibson, J, Ho, P, Hart, D, Joshua, D. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. British journal of haematology. 2004; 125:743-8

Chern, B, Joseph, D, Joshua, D, Pittman, K, Richardson, G, Schou, M, Lowe, S, Copeman, M, De Abreu Lourenco, R, Lynch, K. Bisphosphonate infusions: patient preference, safety and clinic use. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2004; 12:463-6

Horvath, N, Hahn, U, Joshua, D, Dyson, P, Gibson, J, Stevens, J, Rawling, T, Barrow, L, Brown, R, Stephens, S, Gower, G, Norman, J, Mills, B, To, L. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach. Internal medicine journal. 2004; 34:167-75

Brown, R, Murray, A, Pope, B, Sze, D, Gibson, J, Ho, P, Joshua, D. B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation. Leukemia & lymphoma. 2004; 45:363-71

Joshua, D, Joshua, D, Gibson, J, Ho, P, brown, R. The immune system in myeloma. In: Multiple myeloma and related disorders. UK: Arnold 2004. p. 29-46.

Joshua, D, Joshua, D, Gibson, J, Ho, P, brown, R. The immune system in myeloma. In: Multiple myeloma and related disorders. UK: Arnold 2004. p. 29-46.

Ho, P, Gibbins, J, Joshua, D. Treatment of multiple myeloma: current management and new approaches. American journal of cancer. 2004; 3:47-66

2003

Barrow, L, Brown, R, Murray, A, Sze, D, Pope, B, Gibson, J, Hart, D, Joshua, D. CMRF44+ dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination. Leukemia and Lymphoma. 2003; 44:2117-2122

Sze, D, Brown, R, Yuen, E, Gibson, J, Ho, J, Raitakari, M, Basten, A, Joshua, D, Fazekas de St Groth, B. Clonal cytotoxic T cells in myeloma. Leukemia & lymphoma. 2003; 44:1667-1674

Szea, D, Brown, R, Yang, S, Gibson, J, Ho, J, Fazekas de St Groth, B, Basten, A, Joshua, D. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia & lymphoma. 2003; 44:1557-1568

Raitakari, M, Brown, R, Gibson, J, Joshua, D. T cells in myeloma. Hematological Oncology. 2003; 21:33-42

2001

Brown, R, Pope, B, Murray, A, Esdale, W, Sze, D, Gibson, J, Ho, P, Hart, D, Joshua, D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001; 98:2992-2998

Sze, D, Giesajtis, G, Brown, R, Raitakari, M, Gibson, J, Ho, J, Baxter, A, Fazekas de St Groth, B, Basten, A, Joshua, D. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood. 2001; 98:2817-2827

Bradstock, K, Matthews, J, Young, G, Lowenthal, R, Baxter, H, Arthur, C, Bashford, J, Brighton, T, Cannell, P, Dunlop, L, Durrant, S, Enno, A, Eliadis, P, Gill, D, Gillett, A, Gottlieb, D, Januszewicz, H, Joshua, D, Leahy, M, Schwarer, A, Taylor, K, , A. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2001; 15:1331-8

Ho, P, Brown, R, Pelka, G, Basten, A, Gibson, J, Joshua, D. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood. 2001; 97:490-5

Ho, L, Ayling, J, Prosser, I, Kronenberg, H, Iland, H, Joshua, D. Missense C168T in the Wiskott--Aldrich Syndrome protein gene is a common mutation in X-linked thrombocytopenia. British Journal of Haematology. 2001; 112:76-80